Enterprise Value
89.57M
Cash
47.83M
Avg Qtr Burn
-3.344M
Short % of Float
9.57%
Insider Ownership
35.07%
Institutional Own.
12.05%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XPro1595 (XPro™) Details Alzheimer's disease | Phase 2 Data readout | |
LIVNate Details NASH-induced significant or severe fibrosis, Liver disease | Phase 2 Update | |
INB03 + trastuzumab-deruxtecan Details Cancer, Pancreatic cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer , Gastric cancer | Phase 2 Update | |
XPro1595 (XPro™) (pegipanermin fr) Details Major depressive disorder, Mental health, Treatment Resistant Depression | Phase 2 Update | |
INKmune™ Details Cancer, Prostate cancer, Castration-resistant prostate cancer | Phase 1/2 Initiation | |
INKmune™ Details Cancer, Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1 Data readout | |
Quellor™ Details COVID-19 | Failed Discontinued |